Stockreport

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics, Inc.  (EWTX) 
PDF – Completed enrollment of the GRAND CANYON global pivotal study of sevasemten in Becker muscular dystrophy (Becker) –– Announced positive top-line results from Phase 2 C [Read more]